Your browser is no longer supported. Please, upgrade your browser.
KRYS Krystal Biotech, Inc. daily Stock Chart
KRYS [NASD]
Krystal Biotech, Inc.
Index- P/E- EPS (ttm)-1.17 Insider Own11.50% Shs Outstand17.04M Perf Week4.13%
Market Cap1.11B Forward P/E- EPS next Y-2.06 Insider Trans-2.49% Shs Float11.48M Perf Month27.05%
Income-17.40M PEG- EPS next Q-0.33 Inst Own65.20% Short Float16.07% Perf Quarter47.75%
Sales- P/S- EPS this Y-26.50% Inst Trans15.02% Short Ratio10.58 Perf Half Y127.28%
Book/sh12.01 P/B5.43 EPS next Y-68.90% ROA-10.70% Target Price71.60 Perf Year162.07%
Cash/sh11.92 P/C5.47 EPS next 5Y- ROE-11.10% 52W Range16.82 - 66.50 Perf YTD213.91%
Dividend- P/FCF- EPS past 5Y- ROI- 52W High-1.91% Beta-
Dividend %- Quick Ratio54.90 Sales past 5Y- Gross Margin- 52W Low287.81% ATR3.94
Employees37 Current Ratio54.90 Sales Q/Q- Oper. Margin- RSI (14)71.99 Volatility5.87% 7.21%
OptionableNo Debt/Eq0.00 EPS Q/Q4.70% Profit Margin- Rel Volume0.66 Prev Close64.23
ShortableYes LT Debt/Eq0.00 EarningsNov 04 Payout- Avg Volume174.46K Price65.23
Recom1.70 SMA2013.47% SMA5038.74% SMA20066.42% Volume114,634 Change1.56%
Sep-24-19Initiated Goldman Neutral $60
Aug-06-19Reiterated H.C. Wainwright Buy $56 → $59
Jun-24-19Reiterated H.C. Wainwright Buy $38 → $56
Jun-24-19Reiterated Chardan Capital Markets Buy $57.50 → $75
May-30-19Initiated Guggenheim Buy
Sep-11-18Initiated Cantor Fitzgerald Overweight $28
Dec-14-19 09:42PM  Hedge Funds Dropped The Ball On Krystal Biotech, Inc. (KRYS) Insider Monkey
Dec-12-19 11:56AM  The Zacks Analyst Blog Highlights: ACADIA, Compugen, Cue Biopharma, Epizyme and Krystal Biotech Zacks
Dec-11-19 09:04AM  5 Biotech Stocks Up More Than 100% This Year So Far Zacks
Dec-03-19 08:50AM  Krystal Biotech, Inc. (KRYS) Shares March Higher, Can It Continue? Zacks
Nov-26-19 08:00AM  Krystal Biotech to Present at the Piper Jaffray 31st Annual Healthcare Conference GlobeNewswire
Nov-14-19 10:00AM  Here's Why Krystal Biotech, Inc. (KRYS) is a Great Momentum Stock to Buy Zacks
Nov-04-19 08:00AM  Krystal Biotech Reports Third Quarter 2019 Financial and Operating Results GlobeNewswire
Oct-30-19 05:23PM  Here is What Hedge Funds Think About Krystal Biotech, Inc. (KRYS) Insider Monkey
Oct-29-19 08:00AM  Krystal Biotech Announces Final Update from Phase 1/2 Clinical Trial of KB103 ("bercolagene telserpavec," "B-VEC") GlobeNewswire
Oct-10-19 08:00AM  Krystal Biotech Receives Positive EMA Opinion on Orphan Designation for KB105 to Treat Patients With TGM1 Deficient Autosomal Recessive Congenital Ichthyosis GlobeNewswire
Oct-04-19 08:38AM  Before You Buy Krystal Biotech, Inc. (NASDAQ:KRYS), Consider Its Volatility Simply Wall St.
Sep-30-19 08:00AM  Krystal Biotech to Present at the Cantor 2019 Global Healthcare Conference and Chardan's 3rd Annual Genetic Medicines Conference GlobeNewswire
Sep-27-19 08:00AM  Krystal Biotech Announces Granting of its First Foreign Patent and Reinforces its IP Portfolio with a New U.S. Patent GlobeNewswire -13.62%
Sep-04-19 08:00AM  Krystal Biotech Announces Initiation of Phase 1/2 Study of KB105 in Transglutaminase-1 (TGM1) Deficient Autosomal Recessive Congenital Ichthyosis (ARCI) GlobeNewswire
Aug-27-19 04:05PM  Krystal Biotech Announces Attendance at Citis 14th Annual Biotech Conference GlobeNewswire
Aug-14-19 03:12PM  Have Insiders Been Buying Krystal Biotech, Inc. (NASDAQ:KRYS) Shares? Simply Wall St.
Aug-05-19 08:00AM  Krystal Biotech Reports Second Quarter 2019 Financial and Operating Results GlobeNewswire -6.66%
Jul-01-19 09:05AM  Krystal Biotech, Inc. Added to the Russell 2000 Index GlobeNewswire +10.28%
08:19AM  3 Small-Cap Biotech Stocks That Soared Last Week Motley Fool
Jun-27-19 11:18AM  Hedge Funds Have Never Been This Bullish On Krystal Biotech, Inc. (KRYS) Insider Monkey
Jun-25-19 01:15PM  Krystal Biotech Analyst Lifts Price Target More Than 50% On Positive Phase 2 Data, RMAT Designation Benzinga
07:15AM  The Daily Biotech Pulse: Genfit NASH Drug In China, Conatus Explores Sale, Gilead Stitches Up Immuno-Oncology Partnership Benzinga
Jun-24-19 04:31PM  Why NRC Group Holdings, PCM, and Krystal Biotech Jumped Today Motley Fool +41.34%
02:56PM  Krystal Biotech Rallies On Positive Trial Results For Skin Condition Benzinga
11:06AM  Krystal Biotech stock jumps after positive clinical trial results American City Business Journals
10:31AM  Krystal Biotech shares up 27% after company's skin drug receives expedited review designation from FDA MarketWatch
08:00AM  Krystal Biotech Announces Positive Results from Phase 2 Clinical Trial (GEM-2 study) of KB103 and Receives Regenerative Medicine Advanced Therapy (RMAT) Designation from FDA for KB103 GlobeNewswire
Jun-14-19 08:00AM  Krystal Submits Investigational New Drug (IND) Application for KB105, Topical Gene Therapy Candidate for Transglutaminase-1 Deficient Autosomal Recessive Congenital Ichthyosis GlobeNewswire -11.20%
May-15-19 08:00AM  Krystal Biotech to Present at the RBC Capital Markets 2019 Healthcare Conference GlobeNewswire
May-06-19 08:00AM  Krystal Biotech Reports First Quarter 2019 Financial Results and Provides Corporate Update GlobeNewswire
Apr-29-19 08:00AM  Krystal Biotech Announces Five Presentations of Clinical and Preclinical Data at the Society for Investigative Dermatology Annual Meeting GlobeNewswire
Mar-29-19 08:00AM  EMA Grants PRIME Eligibility for KB103 to Treat Dystrophic Epidermolysis Bullosa GlobeNewswire +10.00%
Mar-12-19 08:00AM  Krystal Biotech Reports 2018 Financial Results and Business Progress GlobeNewswire
Mar-07-19 08:58AM  Krystal (KRYS) in Focus: Stock Moves 5.1% Higher Zacks
Mar-06-19 08:00AM  Krystal Biotech Continues Vertical Integration with Official Inauguration of Ancoris Gene Therapy Manufacturing Facility at its Pittsburgh Headquarters GlobeNewswire +5.09%
Mar-04-19 08:00AM  Krystal Strengthens Board of Directors with Appointment of Julian S. Gangolli GlobeNewswire
Mar-01-19 08:00AM  Krystal Biotech to Present at the Cowen and Company 39th Annual Health Care Conference GlobeNewswire
Feb-22-19 08:00AM  Krystal Biotech to Present at the 8th Annual SVB Leerink Global Healthcare Conference GlobeNewswire
Jan-18-19 01:57PM  Danforth Advisors entering Pittsburgh, focusing on life sciences sector American City Business Journals
Jan-15-19 08:00AM  Krystal Biotech Completes Construction of Ancoris - A New GMP Facility for Commercial Manufacturing of a Viral Vector-Based Gene Therapy to Treat Dystrophic Epidermolysis Bullosa GlobeNewswire
Dec-19-18 08:00AM  Krystal Biotech Completes Dosing in the GEM-Phase 2 Study in Pediatric Patients for the Treatment of Dystrophic Epidermolysis Bullosa GlobeNewswire
Nov-21-18 07:55AM  New Research Coverage Highlights VSE, Weyco Group, Funko, B. Riley Financial, Krystal Biotech, and Xcel Brands Consolidated Revenues, Company Growth, and Expectations for 2018 GlobeNewswire
Nov-20-18 08:00AM  Krystal Biotech to Present at Evercore ISI HealthCONx GlobeNewswire
Nov-05-18 08:00AM  Krystal Biotech Reports Third Quarter 2018 Financial Results and Provides Corporate Update GlobeNewswire
Oct-23-18 04:01PM  Krystal Biotech Announces Closing of Public Offering of Common Stock and Exercise in Full of Underwriters Over-Allotment Option GlobeNewswire
Oct-22-18 07:15PM  Krystal Biotech Inc (KRYS) President and CEO Krish S Krishnan Bought $500,000 of Shares GuruFocus.com -6.92%
04:00PM  Chardan Serves as Lead Manager for Krystal Biotech PR Newswire
Oct-18-18 06:03PM  Krystal Biotech Announces Pricing of $60.0 Million Public Offering of Common Stock GlobeNewswire
Oct-17-18 04:01PM  Krystal Biotech Announces Commencement of $60.0 Million Public Offering of Common Stock GlobeNewswire -13.42%
Oct-15-18 07:45AM  Krystal Biotech Announces Positive Interim Results from Placebo-Controlled Phase 1/2 Clinical Trial of KB103 GlobeNewswire +23.92%
Oct-04-18 04:05PM  Krystal Biotech to Present at Chardan Annual Genetic Medicines Conference GlobeNewswire
Oct-01-18 08:00AM  Krystal Biotech to Present at 2018 Cell & Gene Meeting on the Mesa GlobeNewswire
Sep-25-18 08:00AM  Krystal Biotech to Present at Upcoming Cantor Fitzgerald and Ladenburg Thalmann Conferences GlobeNewswire
Aug-29-18 04:05PM  Krystal Biotech to Present at Upcoming B. Riley FBR and H.C. Wainwright Healthcare Investor Conferences GlobeNewswire
Aug-23-18 08:00AM  Krystal Biotechs KB105 Receives Rare Pediatric Disease Designation from the FDA to Treat Patients with TGM-1-deficient Autosomal Recessive Congenital Ichthyosis GlobeNewswire
Aug-17-18 12:31PM  Chardan Capital Markets acts as Sole Placement Agent in $10 Million Securities Purchase PR Newswire +5.38%
Aug-16-18 07:17PM  Krystal Biotech Announces $10 Million Private Placement with Frazier Healthcare Partners GlobeNewswire
Aug-09-18 08:00AM  Krystal Biotechs KB105 Granted Orphan Drug Designation by the FDA to Treat Patients With TGM-1 Deficient Autosomal Recessive Congenital Ichthyosis GlobeNewswire
Aug-06-18 08:00AM  Krystal Biotech Reports Second Quarter 2018 Financial Results and Provides Corporate Update GlobeNewswire
Jul-16-18 08:00AM  Krystal Biotech to Present Update on KB103 Program for Treatment of Dystrophic Epidermolysis Bullosa at debra Care Conference 2018 GlobeNewswire
Jul-13-18 10:05AM  Krystal Biotech (KRYS) Shares March Higher, Can It Continue? Zacks
Jun-08-18 05:29AM  Can the Rally in Krystal Biotech (KRYS) Shares Continue? Zacks +8.91%
May-29-18 07:00AM  Blog Exposure - Krystal Biotechs KB103 Granted Fast Track Designation by FDA for Treatment of Dystrophic Epidermolysis Bullosa ACCESSWIRE
May-24-18 08:00AM  U.S. FDA Grants Fast Track Designation for Krystal Biotechs KB103 for the Treatment of Dystrophic Epidermolysis Bullosa GlobeNewswire
May-10-18 09:18AM  Krystal Biotech Announces Dosing of First Patient in the Phase 1/2 trial of KB103, a First-in-Class Topical Gene Therapy for the Treatment of Dystrophic Epidermolysis Bullosa GlobeNewswire
May-09-18 08:00AM  Krystal Biotech Presents In Vivo KB103 Data at the International Investigative Dermatology Conference that Show Human COL7 Incorporating into Anchoring Fibrils with Proper Structural Orientation GlobeNewswire
May-07-18 08:00AM  Krystal Biotech Reports First Quarter 2018 Financial Results and Provides Corporate Update GlobeNewswire
Apr-26-18 08:00AM  Krystal Biotech Announces FDA Clearance of IND on KB103 to Begin Enrolling Patients for the Treatment of Dystrophic Epidermolysis Bullosa GlobeNewswire
Apr-23-18 07:00AM  Wired News - Krystal Biotech's Lead Product Candidate, KB103, for Treatment of DEB Receives Orphan Medicinal Product Designation in Europe ACCESSWIRE -10.99%
Apr-19-18 08:00AM  Krystal Biotechs KB103 Receives Orphan Medicinal Product Designation in Europe for Dystrophic Epidermolysis Bullosa GlobeNewswire
Apr-18-18 04:01PM  Krystal Biotech Presents Their Skin TARgeted Delivery Platform at the World Orphan Drug Congress USA GlobeNewswire
Mar-27-18 08:00AM  Krystal Submits Investigational New Drug (IND) Application for KB103, Topical Gene Therapy Candidate for Dystrophic Epidermolysis Bullosa GlobeNewswire
Mar-12-18 08:00AM  Krystal Biotech Reports 2017 Financial Results and Business Progress GlobeNewswire
Mar-05-18 08:00AM  Krystal Biotech, Inc. to Present at the 30th Annual ROTH Conference GlobeNewswire -6.75%
Jan-16-18 08:00AM  Krystal Biotech, Inc. Announces Granting of U.S. Composition of Matter Patent Covering Herpes Simplex Virus (HSV) Vectors and Methods of Using the Same to Treat Skin Diseases GlobeNewswire
Oct-20-17 02:16PM  Is Krystal Biotech Inc (KRYS) Still A Cheap Healthcare Stock? Simply Wall St.
Sep-25-17 08:15PM  Krystal Biotech Inc (KRYS) President and CEO Krish S Krishnan Bought $1,000,000 of Shares GuruFocus.com
Sep-24-17 09:57AM  IPO News This Week: Roku, PQ Group Lead 7 Offerings Due Out 24/7 Wall St.
Krystal Biotech, Inc., a gene therapy company, develops and commercializes pharmaceutical products for patients suffering from dermatological diseases in the United States. The company's lead product candidate is KB103, which is in Phase II of a Phase I/II clinical study to treat dystrophic epidermolysis bullosa, a genetic disease. It is also involved in developing KB105 that is in preclinical studies for treating patients with deficient autosomal recessive congenital ichthyosis. The company was formerly known as Krystal Biotech, LLC and changed its name to Krystal Biotech, Inc. in March 2017. Krystal Biotech, Inc. was founded in 2015 and is headquartered in Pittsburgh, Pennsylvania.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Riley Antony AChief Financial OfficerNov 19Option Exercise9.856,25061,5639,050Nov 21 04:05 PM
Krishnan Krish SPresident and CEONov 18Sale52.3322,1211,157,6021,986,462Nov 19 04:03 PM
Krishnan Krish SPresident and CEONov 15Sale50.4127,8791,405,2862,008,583Nov 19 04:03 PM